425: Passage Bio, Remix Therapeutics Amend Merger, Secure Financing

Passage Bio, Inc. and Remix Therapeutics, Inc. have amended their merger agreement, introducing a two-step merger structure and confirming a concurrent financing of approximately $70 million.

Summary

• Passage Bio, Inc. (Passage) and Remix Therapeutics, Inc. (Remix) have entered into an Amended and Restated Merger Agreement, modifying their original agreement from June 24, 2026.
• The transaction will now be structured as a two-step merger: first, Merger Sub merges with Remix, and second, the surviving entity merges with Merger Sub II.
• The parties intend for the merger to qualify as a reorganization under Section 368(a) of the Internal Revenue Code.
• A concurrent financing of approximately $70 million will be consummated immediately prior to the first merger, involving the sale of Remix common stock and/or pre-funded warrants.
• The economic terms of the original merger agreement, including valuation and required financing proceeds, remain unchanged.
• The outside date for closing the merger remains December 24, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, indicating strategic progress in a complex merger and financing scenario.

Positives

• The amendment to the merger agreement and confirmation of the concurrent financing indicate continued strategic progress and commitment to the transaction.
• The transaction is structured to potentially qualify as a tax-free reorganization, which is generally favorable for shareholders.
• The aggregate equity value ascribed to each company and the minimum proceeds required for the concurrent financing remain unchanged, suggesting stability in the deal terms.
• Passage Bio's board of directors has approved the amended agreement and recommended it to stockholders, signaling internal confidence.

Negatives

• The introduction of a two-step merger structure adds complexity to the transaction.
• The filing is primarily a procedural update to the merger agreement and does not contain new clinical or financial performance data for either company.
• The success of the transaction remains contingent on various closing conditions, including stockholder approvals and regulatory clearances.

Risks

• The conditions to the closing of the proposed transaction may not be satisfied, including the failure to obtain stockholder approval or required regulatory clearances.
• There are uncertainties regarding the timing of the consummation of the transaction.
• The ability of Passage Bio and Remix to integrate their businesses successfully and achieve anticipated synergies is not guaranteed.
• The combined company may require additional funding, which may not be available.
• The risk that holders of the Contingent Value Rights (CVRs) may never receive any payments thereunder.
• The risk that the concurrent private placement financing is not consummated.

Future Outlook

The filing does not provide specific forward-looking financial guidance but reiterates the intention to close the merger and concurrent financing, subject to customary closing conditions. The company anticipates that its combined cash position will be sufficient to fund operations into 2028.

Management Comments

• The board of directors of Passage Bio has determined that the transactions contemplated by the Amended and Restated Merger Agreement are fair to, advisable and in the best interests of the Company and its stockholders.
• The board of directors of Remix has determined that the transactions contemplated by the Amended and Restated Merger Agreement are fair to, advisable and in the best interests of Remix and its stockholders.

Industry Context

StockSavvy.ai notes that this amendment reflects a common practice in M&A transactions where deal structures are refined to address regulatory or financing complexities. The focus on a two-step merger and the confirmation of financing are critical steps towards closing.

Stakeholder Impact

• Passage Bio stockholders will vote on the issuance of shares and a change of control.
• Remix stockholders will receive shares of Passage Bio common stock (or pre-funded warrants) in exchange for their Remix equity.
• Investors in the concurrent financing will receive Remix common stock and/or pre-funded warrants, which will convert into Passage Bio securities.
• Holders of Contingent Value Rights (CVRs) will have rights to potential future payments based on specific events related to legacy assets.

Next Steps

• Obtain stockholder approval for the merger and related transactions.
• Satisfy all other closing conditions outlined in the Amended and Restated Merger Agreement.
• Complete the concurrent financing.
• Effect the two-step merger.

Key Dates

Recommendation

The filing is primarily an update on the merger and financing structure, not a performance update. While the continued progress is positive, the inherent risks of merger completion and the early-stage nature of the combined entity's pipeline warrant a hold.

Keywords

Merger Agreement, Amended and Restated, Concurrent Financing, Pre-funded warrants, Stockholder Approval, Tax Reorganization, SEC Filing, Form 8-K